Galactooligosaccharides (GOS) für Irritable Bowel Syndrome (IBS)
B Evidenz Mindestens eine randomisierte Studie unterstützt dies, mit überwiegend konsistenten Ergebnissen.Reduces IBS symptoms (pain, bloating, flatulence) in dose-dependent manner. 3.5 g/day showed better results than 7 g/day (excess fermentation at higher dose).
Fazit
Reduces IBS symptoms (pain, bloating, flatulence) in dose-dependent manner. 3.5 g/day showed better results than 7 g/day (excess fermentation at higher dose).
Key Study Findings
Population: review of prebiotics, probiotics, synbiotics, postbiotics for gastrointestinal inflammation
Population: IBS patients (Rome IV) who improved on FODMAP diet
Population: IBS-D patients (Rome IV)
Population: Adult IBS patients
Population: Adults with constipation-predominant IBS
Population: Laboratory food science study (no human subjects)
Key Statistics
3
Studien
400
Teilnehmer
Positive
Bewertung
Referenced Papers
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
Übliche Dosierungen
- general:
- 2.5-5 g/day
- ibssupport:
- 3.5 g/day (optimal dose; higher doses may increase symptoms)
- infantgutsupport:
- 0.24-0.48 g/100 mL formula (added to infant formula)
Obergrenze: Well-tolerated up to 15 g/day; optimal dose appears to be 3.5-5 g/day
In der Forschung untersuchte Dosierungen
| Dosierung | Dauer | Wirkung | N |
|---|---|---|---|
| None | -- | Positive | -- |
| None | 12 weeks | Negative | 45 |
| None | 4 weeks | Mixed | -- |
| None | -- | Positive | -- |
| 9.2 g/day total (4.6 g twice daily) | 8 weeks | Positive | 34 |
| None | -- | Positive | -- |
| 1e9 CFU/day + GOS 10 g/L | -- | Positive | -- |
| None | -- | Neutral | -- |
Beste Einnahmezeit: With meals; start with lower dose and increase gradually
Safety & Side Effects
Gemeldete Nebenwirkungen
- ⚠ Gas and bloating (especially above 5 g/day; dose-response is U-shaped)
- ⚠ Flatulence at higher doses
- ⚠ Abdominal cramping if dose increased too quickly
- ⚠ May worsen symptoms in FODMAP-sensitive individuals
Bekannte Wechselwirkungen
- ● Other FODMAPs (cumulative fermentation in sensitive individuals)
- ● Lactose-containing products (GOS is derived from lactose; generally safe for lactose-intolerant individuals as GOS itself is lactose-free)
Tolerierbare Höchstaufnahmemenge: Well-tolerated up to 15 g/day; optimal dose appears to be 3.5-5 g/day
Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.
Frequently Asked Questions
Does Galactooligosaccharides (GOS) help with Irritable Bowel Syndrome (IBS)?
How much Galactooligosaccharides (GOS) should I take for Irritable Bowel Syndrome (IBS)?
Are there side effects of Galactooligosaccharides (GOS)?
How strong is the evidence for Galactooligosaccharides (GOS) and Irritable Bowel Syndrome (IBS)?
Related Evidence
Andere Inhaltsstoffe für Irritable Bowel Syndrome (IBS)
References
- [1] Radhika Baheti et al.. Food Res Int. 2026. Interplay of probiotics, prebiotics, synbiotics and postbiotics: a review of their therapeutic potential for gastrointestinal inflammation. doi:10.1016/j.foodres.2026.118598 PubMed
- [2] Prashant Singh et al.. Clin Gastroenterol Hepatol. 2025. Is a Simplified, Less Restrictive Low FODMAP Diet Possible? Results From a Double-Blind, Pilot Randomized Controlled Trial. doi:10.1016/j.cgh.2024.04.021 PubMed
- [3] Shanti Eswaran et al.. Clin Gastroenterol Hepatol. 2025. All FODMAPs Aren't Created Equal: Results of a Randomized Reintroduction Trial in Patients With Irritable Bowel Syndrome. doi:10.1016/j.cgh.2024.03.047 PubMed
- [4] Sheida Zeraattalab-Motlagh et al.. Nutr Rev. 2025. Nutritional Interventions in Adult Patients With Irritable Bowel Syndrome: An Umbrella Review of Systematic Reviews and Meta-analyses of Randomized Clinical … doi:10.1093/nutrit/nuae107 PubMed
- [5] Qi Yao et al.. Nutrients. 2025. Lactobacillus plantarum and Galacto-Oligosaccharides Synbiotic Relieve Irritable Bowel Syndrome by Reshaping Gut Microbiota and Attenuating Mast Cell Hyperactivation. doi:10.3390/nu17101670 PubMed
- [6] Aleksandra M Torbica et al.. Foods. 2025. FODMAP Profile of Wholegrain Pasta. doi:10.3390/foods14040667 PubMed
- [7] Çağlar Akçalı et al.. Sci Rep. 2025. A randomized trial of inulin for bowel symptoms, depression and quality of life in constipation predominant IBS. doi:10.1038/s41598-025-16321-w PubMed
- [8] Aleksandra M Torbica et al.. Foods. 2025. Biotechnological Tools for the Production of Low-FODMAP Wholegrain Wheat and Rye Cookies and Crackers. doi:10.3390/foods14040582 PubMed
- [9] Yusuf Serhat Karakülah et al.. Int J Mol Sci. 2025. Clinical Applications of Bovine Colostrum in GastrointestinaI Disorders: Mechanisms, Evidence, and Therapeutic Potential. doi:10.3390/ijms262110673 PubMed
- [10] Line Graser Jensen et al.. Gastroenterol Res Pract. 2025. Modification of the Low FODMAP Diet Is Feasible in the Treatment of Irritable Bowel Syndrome: A Randomised Crossover Study. doi:10.1155/grp/4152978 PubMed
- [11] Wing-Yan Wong et al.. Food Funct. 2025. A non-pharmacological intervention for insomnia: tryptophan-fructooligosaccharides combination improves sleep in mice via anti-inflammation and gut microbiota modulation. doi:10.1039/d5fo01651g PubMed
- [12] Karen Van den Houte et al.. Gastroenterology. 2024. Efficacy and Findings of a Blinded Randomized Reintroduction Phase for the Low FODMAP Diet in Irritable Bowel Syndrome. doi:10.1053/j.gastro.2024.02.008 PubMed
- [13] Marcus Schmidt et al.. Crit Rev Food Sci Nutr. 2024. FODMAP reduction strategies for nutritionally valuable baking products: current state and future challenges. doi:10.1080/10408398.2023.2195026 PubMed
- [14] Anita Gąsiorowska et al.. J Clin Med. 2024. Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel … doi:10.3390/jcm14010006 PubMed
- [15] María Del C Toca et al.. Arch Argent Pediatr. 2024. Postbiotics: A new member in the biotics family. doi:10.5546/aap.2023-10168.eng PubMed
- [16] Sarvesh V Surve et al.. J Appl Microbiol. 2024. Laboratory domestication of Lactiplantibacillus plantarum alters some phenotypic traits but causes non-novel genomic impact. doi:10.1093/jambio/lxae035 PubMed
- [17] Sean M Garvey et al.. Gastro Hep Adv. 2024. Safety and Tolerability of Microbial Inulinase Supplementation in Healthy Adults: A Randomized, Placebo-Controlled Trial. doi:10.1016/j.gastha.2024.05.013 PubMed
- [18] Justin L Guice et al.. Front Nutr. 2023. Microbial inulinase promotes fructan hydrolysis under simulated gastric conditions. doi:10.3389/fnut.2023.1129329 PubMed
- [19] Woori Na et al.. Nutr Res Pract. 2023. Food contributing to fermentable oligosaccharide, disaccharide, monosaccharide, and polyols intake in Korean adults. doi:10.4162/nrp.2023.17.6.1201 PubMed
- [20] V N Drozdov et al.. Vopr Pitan. 2023. [Clinical efficacy of a modern probiotic for the correction of intestinal microflora in patients with irritable bowel syndrome with diarrhea … doi:10.33029/0042-8833-2023-92-4-92-103 PubMed
- [21] Ashinshana U Illippangama et al.. Carbohydr Polym. 2022. Inulin as a functional ingredient and their applications in meat products. doi:10.1016/j.carbpol.2021.118706 PubMed
- [22] Andrew Thomas et al.. Am J Lifestyle Med. 2022. Dietary Modification for the Restoration of Gut Microbiome and Management of Symptoms in Irritable Bowel Syndrome. doi:10.1177/15598276211012968 PubMed
- [23] J B J Kamphuis et al.. FASEB J. 2022. Increased fermentable carbohydrate intake alters colonic mucus barrier function through glycation processes and increased mast cell counts. doi:10.1096/fj.202100494RRR PubMed
- [24] Anita Gąsiorowska et al.. J Clin Med. 2022. Effects of Microencapsulated Sodium Butyrate, Probiotics and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome: A Study Protocol of … doi:10.3390/jcm11216587 PubMed
- [25] Uzma Mustafa et al.. Indian J Gastroenterol. 2022. The challenges of implementing low fermentable oligo-, di-, mono-saccharides and polyol diet in India: An analysis of available data. doi:10.1007/s12664-022-01250-7 PubMed
- [26] Susie Jung et al.. Nutrients. 2022. A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Multi-Strain Synbiotic in Patients with Functional Diarrhea and High Fecal … doi:10.3390/nu14235017 PubMed
- [27] Diego Currò. Expert Rev Gastroenterol Hepatol. 2022. Current evidence on the therapeutic use of fiber in irritable bowel syndrome. doi:10.1080/17474124.2021.1924057 PubMed
- [28] Marcel Skejovic Joehnke et al.. Food Chem X. 2021. Nutritional and anti-nutritional properties of lentil (Lens culinaris) protein isolates prepared by pilot-scale processing. doi:10.1016/j.fochx.2020.100112 PubMed
- [29] Christopher J Black et al.. Frontline Gastroenterol. 2021. Best management of irritable bowel syndrome. doi:10.1136/flgastro-2019-101298 PubMed
- [30] Cristina Iribarren et al.. Nutrients. 2021. The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profiles and Host Mucosal Response in Patients with Irritable Bowel … doi:10.3390/nu13113836 PubMed
- [31] Johannes Pitsch et al.. Foods. 2021. FODMAP Fingerprinting of Bakery Products and Sourdoughs: Quantitative Assessment and Content Reduction through Fermentation. doi:10.3390/foods10040894 PubMed
- [32] Elodie Schneider et al.. J Nutr. 2021. FODMAP Consumption by Adults from the French Population-Based NutriNet-Santé Cohort. doi:10.1093/jn/nxab207 PubMed
- [33] Teodora Surdea-Blaga et al.. Curr Opin Gastroenterol. 2021. Dietary interventions and irritable bowel syndrome - what really works? doi:10.1097/MOG.0000000000000706 PubMed
- [34] Lena Böhn et al.. Neurogastroenterol Motil. 2021. A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal symptoms in irritable bowel syndrome … doi:10.1111/nmo.14094 PubMed
- [35] Selina R Cox et al.. Gastroenterology. 2020. Effects of Low FODMAP Diet on Symptoms, Fecal Microbiome, and Markers of Inflammation in Patients With Quiescent Inflammatory Bowel Disease … doi:10.1053/j.gastro.2019.09.024 PubMed
- [36] Barbara Skrzydło-Radomańska et al.. Nutrients. 2020. The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant … doi:10.3390/nu12071999 PubMed
- [37] Bridgette Wilson et al.. Am J Gastroenterol. 2020. β-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal Bifidobacteria. doi:10.14309/ajg.0000000000000641 PubMed
- [38] Karin Ried et al.. Nutr Res. 2020. Herbal formula improves upper and lower gastrointestinal symptoms and gut health in Australian adults with digestive disorders. doi:10.1016/j.nutres.2020.02.008 PubMed
- [39] Jasper B J Kamphuis et al.. Gastroenterology. 2020. Lactose and Fructo-oligosaccharides Increase Visceral Sensitivity in Mice via Glycation Processes, Increasing Mast Cell Density in Colonic Mucosa. doi:10.1053/j.gastro.2019.10.037 PubMed
- [40] Jitka Laurent et al.. Int J Food Microbiol. 2020. Variability in yeast invertase activity determines the extent of fructan hydrolysis during wheat dough fermentation and final FODMAP levels in … doi:10.1016/j.ijfoodmicro.2020.108648 PubMed
- [41] Khadijeh Abhari et al.. Eur J Nutr. 2020. Is Bacillus coagulans supplementation plus low FODMAP diet superior to low FODMAP diet in irritable bowel syndrome management? doi:10.1007/s00394-019-02060-y PubMed
- [42] Paul Moayyedi et al.. J Can Assoc Gastroenterol. 2019. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). doi:10.1093/jcag/gwy071 PubMed
- [43] Bridgette Wilson et al.. Am J Clin Nutr. 2019. Prebiotics in irritable bowel syndrome and other functional bowel disorders in adults: a systematic review and meta-analysis of randomized controlled … doi:10.1093/ajcn/nqy376 PubMed
- [44] Xiao Jing Wang et al.. Aliment Pharmacol Ther. 2019. Review article: biological mechanisms for symptom causation by individual FODMAP subgroups - the case for a more personalised approach to … doi:10.1111/apt.15419 PubMed
- [45] Praveena Thirunathan et al.. Crit Rev Food Sci Nutr. 2019. Processing methods for reducing alpha-galactosides in pulses. doi:10.1080/10408398.2018.1490886 PubMed
- [46] Ewa Pejcz et al.. Foods. 2019. Technological Methods for Reducing the Content of Fructan in Wheat Bread. doi:10.3390/foods8120663 PubMed
- [47] Afrin Kamal et al.. Am J Gastroenterol. 2019. Influence of Dietary Restriction on Irritable Bowel Syndrome. doi:10.1038/s41395-018-0241-2 PubMed
- [48] Megan Rossi et al.. Clin Gastroenterol Hepatol. 2018. Volatile Organic Compounds in Feces Associate With Response to Dietary Intervention in Patients With Irritable Bowel Syndrome. doi:10.1016/j.cgh.2017.09.055 PubMed
- [49] C J Tuck et al.. Am J Gastroenterol. 2018. Increasing Symptoms in Irritable Bowel Symptoms With Ingestion of Galacto-Oligosaccharides Are Mitigated by α-Galactosidase Treatment. doi:10.1038/ajg.2017.245 PubMed
- [50] Tobias Pöhnl et al.. J Agric Food Chem. 2018. Impact of Cultivation Method and Cultivar Selection on Soluble Carbohydrates and Pungent Principles in Onions ( Allium cepa L.). doi:10.1021/acs.jafc.8b05018 PubMed
- [51] Bridgette Wilson et al.. J Gastroenterol Hepatol. 2017. Prebiotic inulin-type fructans and galacto-oligosaccharides: definition, specificity, function, and application in gastrointestinal disorders. doi:10.1111/jgh.13700 PubMed
- [52] Jane Varney et al.. J Gastroenterol Hepatol. 2017. FODMAPs: food composition, defining cutoff values and international application. doi:10.1111/jgh.13698 PubMed
- [53] Magdy El-Salhy et al.. Int J Mol Med. 2017. Dietary fiber in irritable bowel syndrome (Review). doi:10.3892/ijmm.2017.3072 PubMed
- [54] F Azpiroz et al.. Neurogastroenterol Motil. 2017. Effects of scFOS on the composition of fecal microbiota and anxiety in patients with irritable bowel syndrome: a randomized, double … doi:10.1111/nmo.12911 PubMed
- [55] Selina R Cox et al.. J Crohns Colitis. 2017. Fermentable Carbohydrates [FODMAPs] Exacerbate Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: A Randomised, Double-blind, Placebo-controlled, Cross-over, Re-challenge Trial. doi:10.1093/ecco-jcc/jjx073 PubMed
- [56] Emma P Halmos. J Gastroenterol Hepatol. 2017. When the low FODMAP diet does not work. doi:10.1111/jgh.13701 PubMed
- [57] Eirini Dimidi et al.. Curr Opin Clin Nutr Metab Care. 2017. Irritable bowel syndrome and diet: where are we in 2018? doi:10.1097/MCO.0000000000000416 PubMed
- [58] Jennifer Erickson et al.. Nutr J. 2017. Gastrointestinal tolerance of low FODMAP oral nutrition supplements in healthy human subjects: a randomized controlled trial. doi:10.1186/s12937-017-0256-3 PubMed
- [59] H M Staudacher et al.. Aliment Pharmacol Ther. 2017. Editorial: metabolic adaptation of colonic microbiota to galactooligosaccharides - good news for prebiotics in irritable bowel syndrome? doi:10.1111/apt.13976 PubMed
- [60] Danuta Owczarek et al.. World J Gastroenterol. 2016. Diet and nutritional factors in inflammatory bowel diseases. doi:10.3748/wjg.v22.i3.895 PubMed
- [61] Markku Hillilä et al.. Scand J Gastroenterol. 2016. Does oral α-galactosidase relieve irritable bowel symptoms? doi:10.3109/00365521.2015.1063156 PubMed
- [62] Martin Raithel et al.. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2016. [Non-allergic gluten sensitivity. A controversial disease - or not yet sufficiently explored?]. doi:10.1007/s00103-016-2366-z PubMed
- [63] Marina Iacovou et al.. J Neurogastroenterol Motil. 2015. The Low FODMAP Diet and Its Application in East and Southeast Asia. doi:10.5056/jnm15111 PubMed
- [64] Heidi M Staudacher et al.. J Nutr. 2012. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. doi:10.3945/jn.112.159285 PubMed
- [65] Michael de Vrese. Menopause Int. 2009. Health benefits of probiotics and prebiotics in women. doi:10.1258/mi.2009.009008 PubMed
- [66] Angelo Andriulli et al.. J Clin Gastroenterol. 2008. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized … doi:10.1097/MCG.0b013e31817fadd6 PubMed
- [67] S Macfarlane et al.. Aliment Pharmacol Ther. 2006. Review article: prebiotics in the gastrointestinal tract. doi:10.1111/j.1365-2036.2006.03042.x PubMed
- [68] W Scheppach et al.. Br J Nutr. 2001. Beneficial health effects of low-digestible carbohydrate consumption. doi:10.1079/bjn2000259 PubMed
- [69] M Olesen et al.. Am J Clin Nutr. 2000. Efficacy, safety, and tolerability of fructooligosaccharides in the treatment of irritable bowel syndrome. doi:10.1093/ajcn/72.6.1570 PubMed
FDA-Haftungsausschluss: Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.